SCHEMBL4716752

SCHEMBL4716752

c1ccc(COc2ccc(-c3cc(Nc4cccc5cnccc45)ncn3)cc2)cc1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TRPV1 Q8NER1 3/20 0.45
PRMT5 O14744 3/20 0.42
ALDH1A1 P00352 3/20 0.42
CYP1A2 P05177 2/20 0.42
CYP3A4 P08684 2/20 0.42
CYP2D6 P10635 2/20 0.42
HSD17B10 Q99714 2/20 0.42
CLK4 Q9HAZ1 2/20 0.42
ACP1 P24666 1/20 0.41
PDE4B Q07343 1/20 0.41
EGFR P00533 2/20 0.40
ERBB2 P04626 1/20 0.40
MAPT P10636 3/20 0.40
KDM4E B2RXH2 2/20 0.40
SMN1; SMN2 Q16637 2/20 0.40
LMNA P02545 1/20 0.40
THRB P10828 1/20 0.40
FAAH O00519 1/20 0.40
NPC1 O15118 1/20 0.39
GALR3 O60755 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4716104 0.87 MAPT (0.53) TRPV1ALDH1A1CYP1A2CYP3A4CYP2D6
SCHEMBL4718692 0.86 TRPV1 (0.49) TRPV1ALDH1A1CYP1A2CYP3A4CYP2D6
SCHEMBL4716052 0.86 PDE4B (0.51) TRPV1ALDH1A1CYP1A2CYP3A4CYP2D6
SCHEMBL4715609 0.85 ACP1 (0.52) TRPV1ALDH1A1CYP1A2CYP3A4CYP2D6
SCHEMBL4718504 0.83 TRPV1 (0.59) TRPV1ALDH1A1PDE4BMAPTKDM4E
SCHEMBL4719637 0.83 TRPV1 (0.48) TRPV1ALDH1A1CYP1A2CYP3A4CYP2D6
SCHEMBL4717175 0.83 ALDH1A1 (0.50) TRPV1ALDH1A1CYP1A2CYP3A4CYP2D6
SCHEMBL4716788 0.82 ABL1 (0.60) TRPV1MAPTKDM4EFAAHMAPK1
SCHEMBL4716401 0.81 TRPV1 (0.48) TRPV1ALDH1A1PDE4BMAPTKDM4E
SCHEMBL4716096 0.81 TRPV1 (0.46) TRPV1ALDH1A1CYP1A2CYP3A4HSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7442701-B2 Amino-heterocycles as VR-1 antagonists for treating pain MERCK SHARP & DOHME LTD. (GB) 2008-10-28 US disclosed
EP-1562934-B1 AMINO-HETEROCYCLES AS VR-1 ANTAGONISTS FOR TREATING PAIN MERCK SHARP & DOHME (GB) 2008-03-26 EP disclosed
US-20060040947-A1 Amino-heterocycles as vr-1 antagonists for treating pain MERCK SHARP & DOHME LTD. (GB) 2006-02-23 US disclosed
EP-1562934-A1 AMINO-HETEROCYCLES AS VR-1 ANTAGONISTS FOR TREATING PAIN MERCK SHARP & DOHME LTD. (GB) 2005-08-17 EP disclosed
WO-2004046133-A1 AMINO-HETEROCYCLES AS VR-1 ANTAGONISTS FOR TREATING PAIN MERCK SHARP & DOHME LIMITED (GB) 2004-06-03 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060040947-A1 Amino-heterocycles as vr-1 antagonists for treating pain OPRL1, CNR1, GPR6 TRPV1 40/4885PRMT5 3987/4885ALDH1A1 2473/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.